OIRA Conclusion of EO 12866 Regulatory Review
| RIN: 0910-ZD68 View EO 12866 Meetings | Received Date: 09/10/2026 |
| Title: Validation of Certain In Vitro Diagnostic Devices for Emerging Pathogens During a Section 564 Declared Emergency; Guidance for Industry and Food and Drug Administration Staff; Availability | |
| Agency/Subagency: HHS / FDA | Stage: Notice |
| Concluded Action: Consistent with Change | Concluded Date: 11/05/2026 |
| Legal Deadline: None | Economically Significant: No |
| Publication Date: | Unfunded Mandates: No |
| Major: No | Related To Homeland Security: No |
| Regulatory Flexibility Analysis Required: No | Small Entities Affected: |
| Federalism Implications: No | Affordable Care Act [Pub. L. 111-148 & 111-152]: No |
| International Impacts: No | Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]: No |
| Pandemic Response: Yes | |
An official website of the United States government




